154.43

0.29% -0.45

After Hours: 154.43

Glaukos Corp (GKOS)

Overview News Price History Option Chain Financials Discussions Forecast

Glaukos Corp stock is traded at $154.43, with a volume of 777.70K. It is down -0.29% in the last 24 hours and down -14.86% over the past month. Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Previous Close:

$154.88

Open:

$154.5

24h Volume:

777.70K

Relative Volume:

0.96

Market Cap:

$9.11B

Revenue:

$551.35M

Net Income/Loss:

$-189.33M

P/E Ratio:

-46.92

EPS:

-3.2916

Net Cash Flow:

$-35.09M

1W Performance:

-5.73%

1M Performance:

-14.86%

6M Performance:

+40.90%

1Y Performance:

+89.55%

1-Day Range:

$151.01

$155.59

1-Week Range:

$151.01

$166.74

52-Week Range:

$73.16

$191.62

Glaukos Corp Stock (GKOS) Company Profile

Name

Glaukos Corp

Sector

Healthcare (1067)

Industry

Medical Devices (139)

Phone

949-367-9600

Address

1 GLAUKOS WAY, ALISO VIEJO, CA

Employee

1,094

Twitter

@GlaukosCorp

Next Earnings Date

2026-11-04

Latest SEC Filings

GKOS's Discussions on Twitter

Compare GKOS vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GKOS Glaukos Corp	154.43	9.11B	551.35M	-189.33M	-35.09M	-3.2916
ABT Abbott Laboratories	101.29	175.27B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	88.64	113.38B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	272.36	104.47B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	43.92	63.65B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.29	49.74B	6.30B	1.07B	1.09B	1.8406

Glaukos Corp Stock (GKOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-06-26	Initiated	H.C. Wainwright	Buy
Oct-27-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-01-25	Initiated	Goldman	Buy
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-11-24	Upgrade	Citigroup	Neutral → Buy
Dec-06-24	Initiated	UBS	Buy
Dec-02-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-10-24	Downgrade	Citigroup	Buy → Neutral
May-06-24	Upgrade	Jefferies	Hold → Buy
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight
Nov-28-23	Initiated	Truist	Buy
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-22-22	Initiated	Mizuho	Neutral
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Oct-14-22	Resumed	Stephens	Overweight
Oct-04-22	Initiated	Needham	Buy
Jul-12-22	Upgrade	Stifel	Hold → Buy
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform
Jan-19-22	Upgrade	Wells Fargo	Underweight → Equal Weight
Jan-18-22	Upgrade	BTIG Research	Neutral → Buy
Nov-03-21	Upgrade	Stephens	Equal-Weight → Overweight
Jul-26-21	Downgrade	Stephens	Overweight → Equal-Weight
Jul-20-21	Downgrade	Wells Fargo	Equal Weight → Underweight
Jul-14-21	Downgrade	Oppenheimer	Outperform → Perform
Jul-14-21	Downgrade	William Blair	Outperform → Mkt Perform
Apr-08-21	Upgrade	Oppenheimer	Perform → Outperform
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Upgrade	Citigroup	Sell → Neutral
Dec-09-20	Initiated	Oppenheimer	Perform
Nov-17-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Oct-08-20	Downgrade	JP Morgan	Neutral → Underweight
Jun-15-20	Initiated	Jefferies	Hold
Mar-05-20	Initiated	Citigroup	Sell
Feb-28-20	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-20	Upgrade	Berenberg	Hold → Buy
Dec-12-19	Downgrade	Wells Fargo	Outperform → Underperform
Sep-30-19	Downgrade	BofA/Merrill	Buy → Underperform
Mar-08-19	Initiated	BTIG Research	Neutral
Aug-30-18	Initiated	Berenberg	Hold
Aug-29-18	Upgrade	JP Morgan	Neutral → Overweight
Aug-03-18	Reiterated	Stifel	Hold
Jun-21-18	Downgrade	JP Morgan	Overweight → Neutral
Apr-13-18	Downgrade	Stifel	Buy → Hold
Mar-01-18	Reiterated	Cantor Fitzgerald	Buy
Mar-02-17	Reiterated	Cantor Fitzgerald	Overweight
Jan-06-17	Upgrade	Stifel	Hold → Buy
Oct-27-16	Initiated	Wells Fargo	Outperform

View All

Glaukos Corp Stock (GKOS) Latest News

Sep 26, 2026

Form 144 GLAUKOS Corp For: 26 September By Investing.com - Investing.com Nigeria

Sep 26, 2026

Sep 25, 2026

A Glaukos (NYSE: GKOS) officer proposes selling 1,615 shares on September 25. - Stock Titan

Sep 25, 2026

Sep 24, 2026

Presbyopia Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | AbbVie, Orasis Pharma, Eyenovia, Glaukos Corp., Ocuphire Pharma, Novartis - Barchart.com

Sep 24, 2026

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now - Yahoo Finance

Sep 24, 2026

Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada

Sep 24, 2026

Glaukos Partners with NBA Champion Stephen Curry to Launch “Could - The National Law Review

Sep 24, 2026

Zacks Investment Research - globes.co.il

Sep 24, 2026

Sep 23, 2026

A Look at Glaukos Corp (GKOS) After 4.0% Decline -- GF Value $15 - gurufocus.com

Sep 23, 2026

Jefferies Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $210 - moomoo.com

Sep 23, 2026

$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today - Benzinga

Sep 23, 2026

Stephen Curry is sharing his story to help families spot signs of a sight-threatening eye disease. - stocktitan.net

Sep 23, 2026

Glaukos stock gains institutional support as Bank of America builds position - AD HOC NEWS

Sep 20, 2026

Sep 18, 2026

Glaukos chief development officer Tomas Navratil sells $243k in shares - Investing.com

Sep 18, 2026

Sep 16, 2026